NO20054441L - G-laktamderivater som prostaglandinagonister - Google Patents

G-laktamderivater som prostaglandinagonister

Info

Publication number
NO20054441L
NO20054441L NO20054441A NO20054441A NO20054441L NO 20054441 L NO20054441 L NO 20054441L NO 20054441 A NO20054441 A NO 20054441A NO 20054441 A NO20054441 A NO 20054441A NO 20054441 L NO20054441 L NO 20054441L
Authority
NO
Norway
Prior art keywords
lactam derivatives
prostaglandin agonists
prostaglandin
agonists
lactam
Prior art date
Application number
NO20054441A
Other languages
English (en)
Inventor
Gian Luca Araldi
Srinivasa Karra
Zhong Zhao
Nadia Brugger
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20054441L publication Critical patent/NO20054441L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen angår y-laktamderivater, da spesielt for anvendelse som medikamenter, så vel som farmasøytiske preparater og sammensetninger som inneholder slike y-laktamderivater.Nevnte y-derivater kan brukes ved behandlingen og/eller for å forebygge astma, hypertensjon, osteoporose, seksuell dysfunksjon eller fruktbarhetslidelser.
NO20054441A 2003-03-03 2005-09-26 G-laktamderivater som prostaglandinagonister NO20054441L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45182903P 2003-03-03 2003-03-03
PCT/EP2004/050239 WO2004078103A2 (en) 2003-03-03 2004-03-02 G-lactam derivatives as prostaglandin agonists

Publications (1)

Publication Number Publication Date
NO20054441L true NO20054441L (no) 2005-09-26

Family

ID=32962645

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054441A NO20054441L (no) 2003-03-03 2005-09-26 G-laktamderivater som prostaglandinagonister

Country Status (11)

Country Link
US (1) US7276531B2 (no)
EP (1) EP1603874B1 (no)
JP (1) JP4662926B2 (no)
AR (1) AR043450A1 (no)
AT (1) ATE394372T1 (no)
AU (1) AU2004216857A1 (no)
CA (1) CA2513652A1 (no)
DE (1) DE602004013559D1 (no)
ES (1) ES2305779T3 (no)
NO (1) NO20054441L (no)
WO (1) WO2004078103A2 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841733A2 (en) 2004-11-08 2007-10-10 Allergan, Inc. Substituted pyrrolidone compounds as prostaglandin ep4 agonists
BRPI0611079A2 (pt) 2005-06-03 2010-08-03 Ono Pharmaceutical Co agentes para a regeneração e/ou proteção de nervos
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
CN103998461B (zh) 2011-09-08 2018-02-02 科德克希思公司 用于合成取代的内酰胺的生物催化剂和方法
CN107802623B (zh) 2012-07-19 2020-10-30 开曼化学股份有限公司 用于ep4介导的骨相关疾病和病症的二氟内酰胺组合物
CA2882138C (en) * 2012-08-21 2020-10-27 Allergan, Inc. Process for the synthesis of substituted gamma lactams
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
EP2989098B1 (en) * 2013-03-15 2017-05-10 Cayman Chemical Company, Incorporated Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
WO2014144500A2 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
WO2015009991A2 (en) * 2013-07-19 2015-01-22 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
US10875830B2 (en) 2016-07-21 2020-12-29 Conopeo, Inc. Method of treatment
US11083706B2 (en) 2016-07-21 2021-08-10 Conopco, Inc. Lactams for use in the treatment of skin lesions
CN109475525A (zh) 2016-07-21 2019-03-15 荷兰联合利华有限公司 4-(4-氯苯基)-5-亚甲基-吡咯-2-酮和5-亚甲基-4-(对甲苯基)吡咯-2-酮用于治疗革兰氏阴性细菌感染

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU198503B (en) 1987-03-24 1989-10-30 Chinoin Gyogyszer Es Vegyeszet Process for producing triphenyl phosphonium salts
SE9702681D0 (sv) 1997-07-10 1997-07-10 Pharmacia & Upjohn Ab Method and composition for treatment of impotence
KR20010033538A (ko) 1997-12-25 2001-04-25 오노 야꾸힝 고교 가부시키가이샤 ω-시클로알킬-프로스타글란딘 Ｅ２ 유도체
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6235780B1 (en) 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
EP1114816A4 (en) 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
US20010006980A1 (en) 1998-10-15 2001-07-05 Harada Shun-Ichi Methods for stimulating bone formation
BR0016560A (pt) 1999-12-22 2002-09-10 Pfizer Prod Inc Agonistas seletivos do receptor ep4 no tratamento da osteoporose
US20010056060A1 (en) 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
KR20030053063A (ko) 2000-11-27 2003-06-27 화이자 프로덕츠 인코포레이티드 골다공증 치료용 이피4 수용체 선택성 작용제
KR100702368B1 (ko) * 2001-07-16 2007-04-02 에프. 호프만-라 로슈 아게 프로스타노이드 작용제로서의 2 피롤리돈 유도체
AU2002328855B2 (en) * 2001-07-16 2005-11-24 F. Hoffmann-La Roche Ag Prostaglandin Analogues As EP4 Receptor Agonists

Also Published As

Publication number Publication date
JP2006519245A (ja) 2006-08-24
WO2004078103A3 (en) 2004-10-28
WO2004078103A2 (en) 2004-09-16
EP1603874A2 (en) 2005-12-14
ES2305779T3 (es) 2008-11-01
JP4662926B2 (ja) 2011-03-30
AU2004216857A1 (en) 2004-09-16
DE602004013559D1 (de) 2008-06-19
AR043450A1 (es) 2005-07-27
US20060194865A1 (en) 2006-08-31
CA2513652A1 (en) 2004-09-16
ATE394372T1 (de) 2008-05-15
EP1603874B1 (en) 2008-05-07
US7276531B2 (en) 2007-10-02

Similar Documents

Publication Publication Date Title
NO20054441L (no) G-laktamderivater som prostaglandinagonister
SE0301009D0 (sv) Novel compounds
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
SE0302760D0 (sv) New compounds
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
NO20061074L (no) Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
MY145074A (en) Thiazolidin-4-one derivatives
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
NO20075693L (no) Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme
BR0208957A (pt) Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como ligandos de receptor de quimiocina cxc
NO20033732L (no) N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser.
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
MY143367A (en) Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
BR0208741A (pt) Derivados de piperidina
NO20054787D0 (no) Indenderivater som farmasotiske midler
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
WO2007073303A3 (en) Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application